[HTML][HTML] Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
M AlQahtani, A Abdulrahman, A Almadani, SY Alali… - Scientific reports, 2021 - nature.com
Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in
severe disease. This pilot study was undertaken to inform feasibility and safety of further …
severe disease. This pilot study was undertaken to inform feasibility and safety of further …
[HTML][HTML] Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
M AlQahtani, A Abdulrahman, A Almadani… - Scientific …, 2021 - ncbi.nlm.nih.gov
Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in
severe disease. This pilot study was undertaken to inform feasibility and safety of further …
severe disease. This pilot study was undertaken to inform feasibility and safety of further …
[PDF][PDF] Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID‑19
SY Alali, AM Al Zamrooni, AH Hejab… - Scientific …, 2021 - scienceopen.com
Methods This was a prospective, randomized, controlled open label pilot study involving 40
patients with severe COVID-19 disease confirmed by RT-PCR testing 11. All patients gave …
patients with severe COVID-19 disease confirmed by RT-PCR testing 11. All patients gave …
[PDF][PDF] Randomized controlled trial of convalescent plasma therapy against standard therapy in 1 patients with severe COVID-19 disease 2
MD Yousif Alali, M Ronán, M Abduljalil - academia.edu
Background. Convalescent plasma (CP) therapy in COVID-19 disease has been suggested
to 31 improve clinical outcome in severe disease. This pilot study was designed to inform the …
to 31 improve clinical outcome in severe disease. This pilot study was designed to inform the …
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
M AlQahtani, A Abdulrahman, A Almadani, SY Alali… - 2022 - repository.rcsi.com
Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in
severe disease. This pilot study was undertaken to inform feasibility and safety of further …
severe disease. This pilot study was undertaken to inform feasibility and safety of further …
[PDF][PDF] Randomized controlled trial of convalescent plasma therapy against standard therapy in 1 patients with severe COVID-19 disease 2
MD Yousif Alali, M Ronán, M Abduljalil - researchgate.net
Background. Convalescent plasma (CP) therapy in COVID-19 disease has been suggested
to 31 improve clinical outcome in severe disease. This pilot study was designed to inform the …
to 31 improve clinical outcome in severe disease. This pilot study was designed to inform the …
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.
M AlQahtani, A Abdulrahman, A Almadani, SY Alali… - lenus.ie
Methods This was a prospective, randomized, controlled open label pilot study involving 40
patients with severe COVID-19 disease confirmed by RT-PCR testing 11. All patients gave …
patients with severe COVID-19 disease confirmed by RT-PCR testing 11. All patients gave …
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
M AlQahtani, A Abdulrahman, A AlMadani, SY AlAli… - 2020 - pesquisa.bvsalud.org
BackgroundConvalescent plasma (CP) therapy in COVID-19 disease has been suggested
to improve clinical outcome in severe disease. This pilot study was designed to inform the …
to improve clinical outcome in severe disease. This pilot study was designed to inform the …
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
M AlQahtani, A Abdulrahman, A Almadani, SY Alali… - 2021 - pubmed.ncbi.nlm.nih.gov
Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in
severe disease. This pilot study was undertaken to inform feasibility and safety of further …
severe disease. This pilot study was undertaken to inform feasibility and safety of further …
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.
M AlQahtani, A Abdulrahman, A Almadani… - Scientific …, 2021 - search.ebscohost.com
Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in
severe disease. This pilot study was undertaken to inform feasibility and safety of further …
severe disease. This pilot study was undertaken to inform feasibility and safety of further …